PMID- 34191410
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1099-0496 (Electronic)
IS  - 1099-0496 (Linking)
VI  - 56
IP  - 9
DP  - 2021 Sep
TI  - Impact of a pharmacy technician and pharmacist on time to inhaled tobramycin 
      therapy in a pediatric cystic fibrosis clinic.
PG  - 2861-2867
LID - 10.1002/ppul.25554 [doi]
AB  - BACKGROUND: Cystic fibrosis (CF) patients who grow Pseudomonas aeruginosa on 
      respiratory culture are commonly prescribed inhaled tobramycin (TIS) to eradicate 
      the organism. The objective of this study was to determine the impact of a 
      pharmacy technician/pharmacist team, in conjunction with an integrated 
      health-system specialty pharmacy (IHSSP), on the time from positive culture to 
      prescribing and access to TIS in a pediatric CF clinic. METHODS: A retrospective 
      study of CF patients positive for P. aeruginosa who were prescribed TIS for 
      eradication. RESULTS: The study included 20 patients in the pregroup and 42 
      patients in the postgroup. Total median (interquartile range) days from positive 
      culture to TIS being shipped to the patient from the pharmacy was significantly 
      different: 15 (10.25-21) days in the pregroup and 9 (7-14) days in the post 
      groups (p = .005). The time from positive culture to TIS prescribing was 
      significantly different: 6 (5-12.75) days in the pregroup and 5 (3.75-6) days in 
      the postgroup (p = .01). In the postgroup median time from prescription to the 
      patient receiving the TIS was significantly different between the two groups 2 
      (2-5) days IHSSP group versus 6 (3-9) external specialty pharmacy group 
      (p = .003). Time from prescription to prior authorization approval was the same 
      in both groups. CONCLUSIONS: The addition of the pharmacy team reduced time from 
      culture to TIS being received by the patient. Patients able to fill at the IHSSP 
      received their medication sooner than an external specialty pharmacy. The study 
      shows the benefit of an integrated pharmacy model in conjunction with an IHSSP.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Burrus, Tiffany E
AU  - Burrus TE
AD  - Department of Pharmacy, Indiana University Health, Indianapolis, Indiana, USA.
FAU - Vogt, Hilary
AU  - Vogt H
AD  - Department of Pharmacy, Indiana University Health, Indianapolis, Indiana, USA.
FAU - Pettit, Rebecca S
AU  - Pettit RS
AUID- ORCID: 0000-0002-6049-0481
AD  - Department of Pharmacy, Riley Hospital for Children at Indiana University Health, 
      Indianapolis, Indiana, USA.
LA  - eng
PT  - Journal Article
DEP - 20210707
PL  - United States
TA  - Pediatr Pulmonol
JT  - Pediatric pulmonology
JID - 8510590
RN  - 0 (Anti-Bacterial Agents)
RN  - VZ8RRZ51VK (Tobramycin)
SB  - IM
MH  - Administration, Inhalation
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Child
MH  - *Cystic Fibrosis/drug therapy
MH  - Humans
MH  - Pharmacists
MH  - Pharmacy Technicians
MH  - *Pseudomonas Infections/drug therapy
MH  - Pseudomonas aeruginosa
MH  - Retrospective Studies
MH  - Tobramycin/therapeutic use
OTO - NOTNLM
OT  - Cystic fibrosis
OT  - Pseudomonas aeruginosa
OT  - Tobramycin
OT  - pediatrics
EDAT- 2021/07/01 06:00
MHDA- 2021/11/25 06:00
CRDT- 2021/06/30 12:45
PHST- 2021/06/02 00:00 [revised]
PHST- 2021/03/04 00:00 [received]
PHST- 2021/06/22 00:00 [accepted]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2021/06/30 12:45 [entrez]
AID - 10.1002/ppul.25554 [doi]
PST - ppublish
SO  - Pediatr Pulmonol. 2021 Sep;56(9):2861-2867. doi: 10.1002/ppul.25554. Epub 2021 
      Jul 7.